Navigation Links
Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
Date:7/25/2012

SAN DIEGO, July 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2012 financial results after the Nasdaq market closes on Tuesday, July 31, 2012.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, July 31, 2012 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Participants can access the live conference call by dialing 800-862-9098 (US) or 785-424-1051 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600.  A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 800-695-0671 (US) or 402-220-1397 (International) using the conference ID: NBIX. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine-related diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... Oregon and PUNE, India , January 18, 2017 ... Research, titled, "Polyphenol Market by Product Type and by Application: Global Opportunity Analysis ... $757 million in 2015, and is expected to reach $1,127 million by 2022, ... the market in 2015, with two-fifths share, in terms of revenue. ... ...
(Date:1/18/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The global CINV drugs market to grow at a ... Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. To ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact on ... Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... in order to thrive this year? , The passage of the act means devicemakers ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today that Dan Grover ... and marketing strategies. Grover comes with a total of 15 years experience in consumer ... as Executive Vice President of Direct Sales at Traeger® Wood Pellet Grills. , ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... age-related lines and wrinkles. Few people know that popular cosmetic fillers ... Richard Buckley, who is medical director of the MilfordMD Cosmetic Dermatology Surgery & ...
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, China ... ... (PRWEB) January 18, 2017 -- Global public health ... to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking ... for drinking water treatment units. This certification verifies that MicroCeramics’ ...
Breaking Medicine News(10 mins):